Foundation Medicine, MD Anderson Begin Second IMPACT Trial of Genomic Cancer Treatment | GenomeWeb

NEW YORK (GenomeWeb) — The University of Texas MD Anderson Cancer Center and Foundation Medicine will work together to conduct a randomized controlled trial to compare standard treatment with targeted therapies selected based on the molecular alterations in a patient's tumor.

Led by MD Anderson's Apostolia Tsimberidou, the study, IMPACT2, will evaluate whether genomically guided cancer care results in longer progression-free survival in patients with advanced disease.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.